West raises 2026 outlook for West Pharmaceutical stock

Published on 10/29/2026 at 13:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter revenue reached USD 874.5 million, up 8.7 percent year over year. West Pharmaceutical stock costs EUR 380.05 on October 29, 2026.

Guidance and operating signals

Adjusted earnings per share reached USD 2.66 versus a USD 2.20 consensus estimate in the third quarter of 2026.
Full-year adjusted earnings guidance rose to USD 9.38-9.48 on October 29, 2026.
West Pharmaceutical Services had a USD 28.4 billion market capitalization as of October 28, 2026.

West Pharmaceutical, US9553061055, Illustration mit AI erstellt.

West Pharmaceutical Services (ISIN US9553061055) reported third-quarter 2026 revenue of USD 874.5 million on October 29, 2026, an 8.7 percent year-over-year increase. The company also raised its full-year outlook in a release from PRNewswire.

Results lift full-year guidance

Adjusted earnings per share came to USD 2.66 in the third quarter, compared with a USD 2.20 consensus estimate, according to MarketBeat. West raised its full-year adjusted earnings-per-share guidance to USD 9.38-9.48 from USD 8.85-9.05, while full-year revenue guidance increased to USD 3.41-3.42 billion from USD 3.345-3.380 billion, PRNewswire reported.

What changed in 2026?

The operating mix explains why the guidance increase matters. Proprietary Products revenue reached USD 728.8 million in the quarter, up 12.6 percent from the prior-year period, while West Vantage revenue fell 7.3 percent to USD 145.7 million, according to PRNewswire. The contrasting segment performance leaves high-value components as the central growth engine and keeps West Vantage as a counterweight.

Three dated company developments

On September 9, 2026, UBS raised its West target to USD 415 from USD 340, according to MarketScreener. On September 22, 2026, Morgan Stanley upgraded the stock to Overweight from Equalweight and raised its target to USD 400 from USD 365, the same source reported. On October 29, 2026, West reported third-quarter results and lifted its annual outlook.

Dividend dates are next

West declared a quarterly dividend of USD 0.26 per share on October 20, 2026, an 18 percent increase, according to MarketScreener. The record date is November 11, 2026, and payment is scheduled for November 18, 2026.

Stock valuation after results

West Pharmaceutical had a USD 28.4 billion market capitalization as of October 28, 2026, with a 52-week range of USD 223.83 to USD 404.99. The quote remains below that documented high while the earnings update raises the bar for execution in the final quarter.

West Pharmaceutical Services was trading at EUR 380.05 at Lang & Schwarz on October 29, 2026 at 1:13 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of West Pharmaceutical stock.